Company news
Keros Therapeutics, Inc. (NASDAQ:KROS) news
Keros Therapeutics, Inc. news releases on 6ix. Latest, Nov 15, 2021: Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 at the American…
Press releases — page 3
Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 at the American Heart Association 2021 Scientific Sessions
November 14, 2021
Keros Therapeutics to Present at the Jefferies Virtual London Healthcare Conference
November 10, 2021
Keros Therapeutics to Present Results from a Preclinical Study of RKER-012 at the American Heart Association 2021 Scientific Sessions
November 7, 2021
Keros Therapeutics to Present at the 63rd American Society of Hematology Annual Meeting and Exposition, Including Presenting Additional Data from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes
November 3, 2021
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results
November 3, 2021
Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension-Associated Bone Loss at the American Society for Bone and Mineral Research 2021 Annual Meeting
October 3, 2021
Keros Therapeutics to Participate in Two Upcoming Healthcare Conferences
September 1, 2021
Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
August 4, 2021
Keros Therapeutics Appoints Simon Cooper, M.B.B.S. as Chief Medical Officer
August 1, 2021
Keros Therapeutics Announces Preliminary Results from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes
June 21, 2021
Keros Therapeutics Presents Preclinical Data from ALK2 and KER-050 Hematology Programs at the European Hematology Association EHA2021 Virtual Congress
June 10, 2021
Keros Therapeutics to Present at the Jefferies Virtual Healthcare Conference
May 26, 2021
Keros Therapeutics Announces Issuance of U.S. Patent for Use of Therapeutic Proteins in Treatment of Musculoskeletal Disorders
May 24, 2021
Keros Therapeutics Presents Results from Preclinical Study of KER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference
May 13, 2021
Keros Therapeutics to Present at the Virtual 26th Annual Congress of the European Hematology Association
May 11, 2021
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results
May 5, 2021
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
March 24, 2021
Keros Therapeutics Presents Results from Preclinical Studies of KER-050 and ALK2 Inhibitors at the European School of Haematology (ESH) 2nd Translational Research E-Conference
March 4, 2021
Keros Therapeutics to Present at the H.C. Wainwright Global Life Sciences 2021 Virtual Conference
March 1, 2021
Keros Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
February 16, 2021
Keros Therapeutics Announces Addition to NASDAQ Biotechnology Index
December 20, 2020
Keros Therapeutics Appoints Mary Ann Gray, Ph.D., to its Board of Directors
December 16, 2020
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its ALK2 Inhibitor Program, Including KER-047 Phase 1 Data, and KER-050 Preclinical Data, at the Virtual 62nd American Society of Hematology Annual Meeting and Exposition
December 6, 2020
Keros Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
November 16, 2020
Keros Therapeutics Announces Pricing of Public Offering of Common Stock
November 11, 2020
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results
November 9, 2020
Keros Therapeutics to Present at the Virtual 62nd American Society of Hematology Annual Meeting and Exposition
November 3, 2020
Keros Therapeutics, Inc. Announces Dosing of First Participants in Phase 2 Clinical Trial of KER-050 in Myelodysplastic Syndromes (MDS)
October 19, 2020
Keros Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 13, 2020
Keros Therapeutics Presents Results from Preclinical Studies Investigating KER-012 at the American Society for Bone and Mineral Research 2020 Annual Meeting
September 10, 2020
Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results
August 12, 2020
Keros Therapeutics to be Featured on The Balancing Act's "Behind the Mystery" Rare Disease Series
August 9, 2020
Keros Therapeutics, Inc. Announces Completion of Dosing of Planned Cohorts in KER-047 Phase 1 Trial and Provides Program Update
August 3, 2020
Keros Therapeutics Set to Join Russell 2000® Index
June 25, 2020
Keros Therapeutics Presents Results from Clinical and Preclinical Studies Investigating KER-050, along with Preclinical Data from its ALK2 Inhibitor Program, at the European Hematology Association 2020 Annual Meeting
June 11, 2020
Keros Therapeutics To Present At The Jefferies 2020 Virtual Healthcare Conference
May 27, 2020
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results
May 21, 2020
Keros Therapeutics to Present at the Virtual 25th Annual Congress of the European Hematology Association
May 13, 2020
Keros Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 12, 2020
Keros Therapeutics Announces Pricing of Initial Public Offering of Common Stock
April 6, 2020